Parkinson's disease is a progressive neurodegenerative disorder characterized by a
selective loss of dopamine in the striatum. Problems remain in the accurate diagnosis of …

The imaging of dopamine transporter (DAT) with 99mTc-TRODAT-1 ([2-[[2-[[[3-(4-
chlorophenyl)-8-methyl-8-azabicyclo [3, 2, 1] oct-2-yl] methyl](2-mercaptoethyl) amino] ethyl] …

Nigral dopaminergic projections to the striatum are targeted in Parkinson's disease (PD).
The extent of the degeneration of the dopaminergic system in PD can be visualised by …

Objective (s): 99m Tc-TRODAT-1, which binds to the dopamine transporter, could be used to
image the dopaminergic system in diagnosis of Parkinson's disease (PD). PD can be …

99mTc-TRODAT-1 ([2-[[2-[[[3-(4-chlorophenyl)-8-methyl-8-azabicyclo [3, 2, 1] oct-2-yl]
methyl](2-mercaptoethyl) amino] ethyl] amino] ethanethiolato (3-)-N2, N2′, S2, S2′] oxo-[1 …

Functional brain imaging targeting the presynaptic dopamine nerve terminal of the
nigrostriatal system has been used for monitoring disease progression and evaluating …

The aim of this study was to use brain SPECT to differentiate vascular parkinsonism (VP)
from Parkinson's disease. Methods: Fourteen VP patients (age range, 59–87 y; mean age …

We evaluated the diagnostic accuracy of SPECT imaging using [99mTc] TRODAT-1
(TRODAT), a relatively inexpensive technetium-labeled dopamine transporter ligand, in …

Imaging of dopamine transporters (DATs) in the brain using [99 Tc m] TRODAT-1 showed
excellent pharmacokinetics for estimation of transporter concentrations. It has been reported …

In the past 10 years, significant progress has been made in using a technetium-99m
dopamine transporter imaging agent,[99mTc] TRODAT, for routine clinical studies …